17,261 trials
Uterine Cancer
Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Locally Advanced or Metastatic NRAS Mutant Melanoma
Primary: Number of Dose Limiting Toxicities (Phase Ib) — 2; 0; 1; 3 occurrence
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Objective Response Rate (ORR) — 60.0 percentage of participants
Dermatitis, Eczematous
Primary: Number of Participants With Patch Test Responses — 0; 105; 16; 0 Participants
Acute Otitis Media
Primary: Number of Participants With Adverse Events — 48; 36 Participants
Adult Liposarcoma · Metastatic Liposarcoma · Metastatic Osteosarcoma
Primary: Progression Free Survival at 12 Weeks for Patients With Soft Tissue Sarcoma (STS) Treated With Pazopanib and Oral Topotecan — 57.5 percentage of patients progression free
Eosinophilic Esophagitis
Primary: Change From Baseline in Peak Eosinophil Count — 63.3; 67.7; 58.9; -11.2 eosinophils per high power field
Pancreatic Cancer
Primary: Number of Participants With Resectability Rate — 15 Participants
Corneal Neovascularization · Corneal Graft Failure
Primary: Endothelial Rejection Rate — 2; 5 Participants — p=0.10
Schizophrenia
Primary: Prepulse Inhibition — 30.4; 25.5; 23.7; 2.6 % inhibition of startle
Parkinson's Disease · Off Episodes of Parkinson Disease
Primary: Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method…
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…
End Stage Renal Disease · Chronic Kidney Disease Stage 5 · ESRD
Primary: Change in Mean Weekly Interdialytic Weight Gain (IDWG) — -0.26; -0.23 kilograms — p=0.46
Metastatic Renal Cell Cancer
Primary: Median Progression-free Survival — 8.8 months